Tag Archives: Andrew Fein

H.C. Wainwright Maintains a Hold Rating on Syros Pharmaceuticals (SYRS)

H.C. Wainwright analyst Andrew Fein maintained a Hold rating on Syros Pharmaceuticals (SYRS – Research Report) today and set a price target of $10.00. The company’s shares closed last Monday at $5.02, close to its 52-week low of $4.88. According

Analysts Offer Insights on Healthcare Companies: Sunesis Pharma (NASDAQ: SNSS) and SAGE Therapeutics (NASDAQ: SAGE)

Analysts fell to the sidelines weighing in on Sunesis Pharma (SNSS – Research Report) and SAGE Therapeutics (SAGE – Research Report) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks. Sunesis Pharma (SNSS) H.C.

H.C. Wainwright Reaffirms Their Buy Rating on Pulmatrix (PULM)

H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Pulmatrix (PULM – Research Report) on November 8 and set a price target of $10.00. The company’s shares closed last Monday at $0.80, close to its 52-week low of $0.61.

Blueprint Medicines (BPMC) Receives a Buy from H.C. Wainwright

H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Blueprint Medicines (BPMC – Research Report) today and set a price target of $100.00. The company’s shares closed last Monday at $74.10. According to TipRanks.com, Fein is a 4-star analyst

Strongbridge Biopharma (SBBP) Receives a Buy from H.C. Wainwright

H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Strongbridge Biopharma (SBBP – Research Report) today and set a price target of $18.00. The company’s shares closed last Monday at $1.59, close to its 52-week low of $1.57. According

Analysts Are Bullish on These Healthcare Stocks: Amarin (AMRN), Kura Oncology (KURA)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Amarin (AMRN – Research Report) and Kura Oncology (KURA – Research Report) with bullish sentiments. Amarin (AMRN) In a report released today,